Gaurav Chauhan

Gaurav Chauhan

Auto-generated profile, based on publicly available information

Gaurav Chauhan

Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
MGManit Gandhi
Manit Gandhi
PBPriyanka Bhatt
Priyanka Bhatt
GCGaurav Chauhan
Gaurav Chauhan
SGSarita Gupta
Sarita Gupta
AMAmbikanandan Misra
Ambikanandan Misra
RMRajashree Mashru
Rajashree Mashru

6 October 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CRChitra Rawat
Chitra Rawat
SBSalma Ben-Salem
Salma Ben-Salem
NSNidhi Singh
Nidhi Singh
GCGaurav Chauhan
Gaurav Chauhan
ARAnja Rabljenovic
Anja Rabljenovic
HHHannelore Heemers
Hannelore Heemers
Prostate cancer remains the second leading cause of cancer death in men in Western cultures. A deeper understanding of the mechanisms by which prostate cancer cells divide to support tumor growth could help devise strategies to overcome treatment resistance and improve survival. Here, we identified that the mitotic AGC family protein kinase citron kinase (CIT) is a pivotal regulator of prostate cancer growth that mediates prostate cancer cell interphase progression. Increased CIT expression correlated with prostate cancer growth induction and aggressive prostate cancer progression, and CIT was overexpressed in prostate cancer compared with benign prostate tissue. CIT overexpression was controlled by an E2F2–Skp2–p27 signaling axis and conferred resistance to androgen-targeted treatment strategies. The effects of CIT relied entirely on its kinase activity. Conversely, CIT silencing inhibited the growth of cell lines and xenografts representing different stages of prostate cancer progression and treatment resistance but did not affect benign epithelial prostate cells or nonprostatic normal cells, indicating a potential therapeutic window for CIT inhibition. CIT kinase activity was identified as druggable and was potently inhibited by the multikinase inhibitor OTS-167, which decreased the proliferation of treatment-resistant prostate cancer cells and patient-derived organoids. Isolation of the in vivo CIT substrates identified proteins involved in diverse cellular functions ranging from proliferation to alternative splicing events that are enriched in treatment-resistant prostate cancer. These findings provide insights into the regulation of aggressive prostate cancer cell behavior by CIT and identify CIT as a functionally diverse and druggable driver of prostate cancer progression.Significance: The poorly characterized protein kinase citron kinase is a therapeutic target in prostate cancer that drives tumor growth by regulating diverse substrates, which control several hallmarks of aggressive prostate cancer progression.See related commentary by Mishra et al., p. 4008

1 December 2018 in Asian Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PKPrachi D. Karia
Prachi D. Karia
LPLaxmi A. Patil
Laxmi A. Patil
MVMitul S. Vakani
Mitul S. Vakani
GCGaurav M. Chauhan
Gaurav M. Chauhan
SGSarita S. Gupta
Sarita S. Gupta
KPKirti V. Patel
Kirti V. Patel

1 July 2025 in Mucosal Immunology
Verified
Journal Article
Open access
GCGaurav Chauhan
Gaurav Chauhan
IVIdo Veisman
Ido Veisman
FRFlorian Rieder
Florian Rieder

1 January 2016 in Biomedical Research Journal
Verified
Journal Article
Closed access
PDF file
SGSarita Gupta
Sarita Gupta
APAkhilesh Prajapati
Akhilesh Prajapati
GCGaurav Chauhan
Gaurav Chauhan
SGSharad Gupta
Sharad Gupta
PPParth Pandya
Parth Pandya
SKSukhbir Kaur
Sukhbir Kaur
Biomed Res J, Official publication of NMIMS (Deemed to be) University Sunandan Divatia School of Science